文献速递神经核医学肿瘤 PET/CT

中枢神经系统药物研发中的影像生物标志物及未来临床效用:神经退行性疾病的经验

Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders.
PubMed 文献 · J Nucl Med · 2022-10-27

中枢神经系统疾病常见且常为慢性,神经退行性疾病如阿尔茨海默病和帕金森病构成重大健康与社会经济挑战,在人口老龄化的工业化国家发病率不断上升。近期研究已确立异常蛋白积累及疾病特异性沉积物在脑内扩散是神经毒性和功能网络破坏的因素。针对这些蛋白病的从小分子到抗体的多种治疗药物现已进入2期和3期临床试验,但这些研究在方法学上具有挑战性。

要点

  • PET和SPECT闪烁显像可在试验中以高特异性探查蛋白沉积等病理生理过程。
  • 这些研究的方法学挑战包括难以准确诊断早期疾病、个体间进展速度缓慢且多变。
  • 理想治疗候选者为病理过程已开始但临床正常的高危或前驱期人群,极难识别。

核心结论

  • 本综述总结了这些影像生物标志物的当前应用情况及其对神经退行性疾病未来管理和中枢神经系统药物研发的意义。

研究设计与样本

  • 本综述总结了PET和SPECT闪烁显像生物标志物在中枢神经系统药物研发中的当前应用及未来管理意义。

主要发现

  • 近期研究已确立异常蛋白积累和疾病特异性沉积物在脑内扩散是神经毒性和功能网络破坏的因素。
  • 针对蛋白病的从小分子到抗体的多种治疗药物现已进入2期和3期临床试验。
  • 这些研究因难以准确诊断早期疾病、个体间进展缓慢且多变而具有方法学挑战。
  • 疗效指标可能因治疗带来的症状改善而混杂,不能反映疾病病程的修饰。
  • 理想治疗候选者为病理过程已开始但临床正常的高危或前驱期人群,极难识别。

局限性

  • 这些研究因难以准确诊断早期疾病而具有方法学挑战。
  • 个体间进展速度缓慢且多变。
  • 疗效指标可能因治疗带来的症状改善而混杂,不能反映疾病病程的修饰。
  • 理想治疗候选者为病理过程已开始但临床正常的高危或前驱期人群,极难识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diseases of the central nervous system are common and often chronic conditions associated with significant morbidity. In particular, neurodegenerative disorders including Alzheimer and Parkinson disease constitute a major health and socioeconomic challenge, with an increasing incidence in many industrialized countries with aging populations. Recent work has established the primary role of abnormal protein accumulation and the spread of disease-specific deposits in brain as a factor in neurotoxicity and disruption of functional networks. A range of therapeutics from small molecules to antibodies targeting these proteinopathies are now in phase 2 and phase 3 clinical trials. These studies are methodologically challenging because of difficulty in accurately diagnosing early disease, the slow and variable rates of progression between individuals, and efficacy measures that may be cofounded by symptomatic improvements due to treatment but not reflecting disease course modification. Further, the ideal candidates for these treatments would be at-risk, or premanifest, persons in whom the pathologic process of the neurodegenerative disorder has begun but who are clinically normal and extremely difficult to identify. Scintigraphic imaging with PET and SPECT in trials offers the opportunity to interrogate pathophysiologic processes such as protein deposition with high specificity. This review summarizes the current implementation of these imaging biomarkers and the implications for future management of neurodegenerative disorders and central nervous system drug development in general.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Seibyl JP. Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders. J Nucl Med. 2022. PMID: 36302659. doi:10.2967/jnumed.122.264773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。